Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Bibliographic Details
Main Authors:	Hassan B. Alkhateeb, Razan Mohty, Patricia Greipp, Radhika Bansal, Matthew Hathcock, Allison Rosenthal, Hemant Murthy, Mohamed Kharfan-Dabaja, Jose C. Bisneto Villasboas, Nora Bennani, Stephen M. Ansell, Mrinal M. Patnaik, Mark R. Litzow, Rong He, Dong Chen, Aref Al-Kali, Saad S. Kenderian, Yi Lin, Mithun Vinod Shah
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-07-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00707-4

Similar Items

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
by: Mark Gurney, et al.
Published: (2023-08-01)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
by: Razan Mohty, et al.
Published: (2022-12-01)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
by: Ahmad Ghorab, et al.
Published: (2022-06-01)

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
by: Arushi Khurana, et al.
Published: (2024-08-01)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
by: Marissa Z. Powell, et al.
Published: (2023-04-01)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
by: Mithun Vinod Shah, et al.
Published: (2022-07-01)

Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
by: Razan Mohty, et al.
Published: (2024-12-01)

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
by: Mohamed A. Kharfan-Dabaja, et al.
Published: (2019-03-01)

“Off-The-Shelf” allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges
by: Razan Mohty, et al.
Published: (2024-07-01)

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
by: Aldo A. Acosta-Medina, et al.
Published: (2023-01-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
by: Naseema Gangat, et al.
Published: (2023-03-01)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
by: Mohty R, et al.
Published: (2023-04-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
by: Ricardo D. Parrondo, et al.
Published: (2022-06-01)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
by: Omran Saifi, et al.
Published: (2023-06-01)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
by: LI Marissa, et al.
Published: (2023-08-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Rami Basmaci, et al.
Published: (2023-08-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
by: Naseema Gangat, et al.
Published: (2022-12-01)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
by: Maymona G. Abdelmagid, et al.
Published: (2023-08-01)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
by: Aref Al-Kali, et al.
Published: (2023-04-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-06-01)

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
by: Julio C. Chavez, et al.
Published: (2019-04-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Bahga Katamesh, et al.
Published: (2023-08-01)

Clinical advances in epigenetic therapies for lymphoma
by: Allison C. Rosenthal, et al.
Published: (2023-03-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Muhamad Oum, et al.
Published: (2023-08-01)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
by: Mithun Vinod Shah, et al.
Published: (2023-04-01)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
by: Pashtoon M. Kasi, et al.
Published: (2016-01-01)

Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy
by: Aung M. Tun, et al.
Published: (2024-01-01)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
by: Talha Badar, et al.
Published: (2023-09-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Amrutha Sai Mittapalli, et al.
Published: (2023-08-01)

Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasms
by: Anmol Baranwal, et al.
Published: (2024-02-01)

Chimeric Antigen Receptor-T Cell Therapy
by: Jochen Buechner, et al.
Published: (2018-02-01)

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
by: Adam M. Kase, et al.
Published: (2022-04-01)

Role of bridging therapy during chimeric antigen receptor T cell therapy
by: Shakthi T. Bhaskar, et al.
Published: (2022-01-01)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
by: Bryanna Reinhardt, et al.
Published: (2023-02-01)

Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
by: William G. Breen, et al.
Published: (2023-08-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
by: Ayalew Tefferi, et al.
Published: (2022-06-01)

Advance in chimeric antigen receptor T therapy in autoimmune diseases
by: Xiaolan Ji, et al.
Published: (2025-03-01)

Chimeric antigen receptor T-cell therapy in autoimmune diseases
by: Jie Liu, et al.
Published: (2024-11-01)